Autolus to present new data at the ASH Annual M...

Arix Bioscience plc

Autolus to present new data at the ASH Annual Meeting

LONDON, 06 November 2019: Arix Bioscience plc (“Arix”, LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today notes that its portfolio company, Autolus Therapeutics Plc (NASDAQ: AUTL) (“Autolus”), has announced four oral and two poster presentations related to its AUTO1, AUTO2 and AUTO3 programmes at the 61st American Society of Hematology (“ASH”) Annual Meeting and Exposition, to be held December 7-10, 2019 in Orlando, FL.

The announcement can be accessed on Autolus' investor website at https://www.autolus.com/investor-relations and full text of the announcement from Autolus is contained below.

ENDS

Enquiries

For more information on Arix, please contact:

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations

Tel: [phone]

[e-mail]  

Media Enquiries

Optimum Strategic Communications 

Mary Clark/ Supriya Mathur

[e-mail]

Tel: [phone]

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange. For further information, please visit www.arixbioscience.com

Autolus Therapeutics to Present New Data on Its Advanced Programmed T Cell Therapies at the 61^st ASH Annual Meeting

-  Company to Present Four Oral Presentations and Two Posters -

LONDON, UK, November 6, 2019 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announced four oral and two poster presentations related to its AUTO1, AUTO2 and AUTO3 programs at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 7-10, 2019 in Orlando, FL.

 â€œWe are pleased that AUTO1 data will be presented in three oral presentations at ASH. The data form the basis for our decision to move AUTO1 into a pivotal clinical trial in adult ALL, our highest priority program,” said Dr. Christian Itin, chairman and chief executive officer of Autolus.  â€œWe are also looking forward to presenting data on our other hematological clinical programs at ASH.  These presentations will further illustrate the significant progress we have made across our clinical portfolio this year.” 

The abstracts have been published today and are available on the ASH website at https://www.hematology.org/Annual-Meeting/Abstracts/.

The oral presentation details are as follows:

Title: AUTO1 – A novel fast off CD19CAR delivers durable remissions and prolonged CAR T cell persistence with low CRS or neurotoxicity in adult ALL

Presenter: Dr Claire Roddie

Session Date and Time:  Saturday, December 7, 2:45 PM Eastern Time

Title: AUTO1 – Therapy of pediatric B-ALL with a lower affinity CD19 CAR leads to enhanced expansion and prolonged CAR T cell persistence in patients with low bone marrow tumor burden, and is associated with a favorable toxicity profile

Presenter: Dr Sara Ghorashian

Session Date and Time:  Saturday, December 7, 2:30 PM Eastern Time

Title: AUTO1 – Clonal dynamics of early responder and long-term persisting CAR-T cells in humans

Presenter: Dr Luca Biasco

Session Date and Time:  Saturday, December 7, 8:15 AM Eastern Time

Title: AUTO3 – Ongoing Phase 1/2 ALEXANDER clinical trial in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL)

Presenter: Dr Kirit Ardeshna

Session Date and Time:  Saturday, December 7, 3:15 PM Eastern Time

The poster presentation details are as follows:

Title: AUTO2 – Phase 1 First-in-Human study of AUTO2, the first chimeric antigen receptor (CAR) T cell targeting APRIL for patients with relapsed/refractory Multiple Myeloma (RRMM)

Presenter: Dr Rakesh Popat

Session Date and Time:  Sunday, December 8, 6:00 PM – 8:00 PM Eastern Time

Title: AUTO3 – Phase 1/2 AMELIA clinical trial of AUTO3 in patients with relapsed/refractory pediatric acute lymphoblastic leukemia (pALL)

Presenter: Professor Persis Amrolia

Session Date and Time:  Sunday, December 8, 6:00 PM – 8:00 PM Eastern Time

About AUTO1 

AUTO1 is a CD19 CAR T cell investigational therapy designed to overcome the limitations in safety - while maintaining similar levels of efficacy - compared to current CD19 CAR T cell therapies. Designed to have a fast target binding off-rate to minimize excessive activation of the programmed T cells, AUTO1 may reduce toxicity and be less prone to T cell exhaustion, which could enhance persistence and improve the T cells' abilities to engage in serial killing of target cancer cells. In 2018, Autolus signed a license agreement under which Autolus acquired global rights from UCL Business plc (UCLB), the technology-transfer company of UCL, to develop and commercialize AUTO1 for the treatment of B cell malignancies. AUTO1 is currently being evaluated in two Phase 1 studies, one in pediatric ALL and one in adult ALL.

About AUTO3

AUTO3 is a programmed T cell therapy containing two independent chimeric antigen receptors targeting CD19 and CD22 that have each been independently optimized for single target activity. By simultaneously targeting two B cell antigens, AUTO3 is designed to minimize relapse due to single antigen loss in patients with B cell malignancies. AUTO3 is currently being tested in pediatric ALL in the AMELIA clinical trial and in diffuse large B cell lymphoma in the ALEXANDER clinical trial.

About AUTO2

AUTO2 is the first dual-targeting programmed T cell product candidate binding to two targets on multiple myeloma cells. AUTO2 uses a human ligand, known as APRIL, which binds to two antigens, B cell Maturation Antigen, or BCMA, and the transmembrane activator and CAML interactor, or TACI, both of which are expressed on the surface of multiple myeloma cancer cells.  AUTO2 is designed to address a key escape route used by hematological cancers in response to T cell therapies. 

About Autolus Therapeutics plc

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.  For more information please visit www.autolus.com.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding Autolus’ financial condition and results of operations, as well as statements regarding the anticipated development of Autolus’ product candidates, including its intentions regarding the timing for providing further updates on the development of its product candidates, and the sufficiency of its cash resources. Any forward-looking statements are based on management's current views and assumptions and involve risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section titled "Risk Factors" in Autolus' Annual Report on Form 20-F filed on November 23, 2018 as well as discussions of potential risks, uncertainties, and other important factors in Autolus' future filings with the Securities and Exchange Commission from time to time. All information in this press release is as of the date of the release, and the company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

# # #

Investor and media contact:

Silvia Taylor

Vice President, Corporate Affairs and Communications

Autolus

[phone]

[e-mail]

UK:

Julia Wilson

[phone]

 [e-mail]